TrialPediatric blood & cancer2020

Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.

Sarah B Whittle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.